All Stories

  1. Underappreciated Health Benefits of Edible Mushrooms in the Dietary Management of CKD
  2. Dietary Advanced Glycation End Products and Cardiovascular-Kidney-Metabolic Complications
  3. Tenapanor: An Update on Evidence of Effectiveness and Guidance on Practical Use
  4. Phosphate Homeostasis in Chronic Kidney Disease with Emphasis in Peritoneal Dialysis
  5. The Physicochemical Approach to Acid-Base Balance
  6. The Role of Kt/V and Creatinine clearance on Assisting Optimization of Serum Phosphorus Levels among Patients on PD
  7. The RAGE Axis: A Relevant Inflammatory Hub in Human Diseases
  8. Industrial Use of Phosphate Food Additives: A Mechanism Linking Ultra-Processed Food Intake to Cardiorenal Disease Risk?
  9. Survey of Peritoneal Dialysis Patients' Challenges and Experiences during the COVID-19 Pandemic: A Multicenter Study in the United States
  10. Dietary Advanced Glycation End Products: Their Role in the Insulin Resistance of Aging
  11. Dietary advanced glycation end-products and postmenopausal hot flashes: A post-hoc analysis of a 12-week randomized clinical trial
  12. Food Additive Use in Ultraprocessed Foods: Can Processing Use of Industrial Additives Contribute to Adverse Health Outcomes in Children?
  13. The Hispanic American longevity paradox: Sofrito and beyond
  14. Outcomes of PD for AKI treatment during COVID-19 in New York City: A multicenter study
  15. Beyond the Urine Anion Gap: In Support of the Direct Measurement of Urinary Ammonium
  16. Dietary advanced glycation products and their associations with insulin sensitivity and body weight: A 16‐week randomized clinical trial
  17. Home Dialysis Utilization Among Underrepresented Groups
  18. Unusual cases of peritonitis: A case series of five patients
  19. Molecular mechanisms and therapeutic targets for diabetic kidney disease
  20. Comparing the effect of peritoneal dialysis cycler type on patient-reported satisfaction, support needs and treatments
  21. Higher Dietary Intake of Advanced Glycation End Products Is Associated with Faster Cognitive Decline in Community-Dwelling Older Adults
  22. Prevalence and Outcomes Associated with Hyperuricemia in Hospitalized Patients with COVID-19
  23. Dietary Advanced Glycation End-Products and Mortality after Breast Cancer in the Women's Health Initiative
  24. The Association between Prevalence of Peritoneal Dialysis versus Hemodialysis and Patients’ Distance to Dialysis-Providing Facilities
  25. Perspective: Plant-based Whole-Grain Foods for Chronic Kidney Disease: The Phytate-Phosphorus Conundrum
  26. Restriction of Dietary Advanced Glycation End Products Induces a Differential Plasma Metabolome and Lipidome Profile
  27. Effect of Advanced Glycation End Products on Cognition in Older Adults with Type 2 Diabetes: Results from a Pilot Clinical Trial
  28. Dietary AGEs as Exogenous Boosters of Inflammation
  29. Presence of SARS-CoV-2 Antibodies in Spent Peritoneal Dialysate
  30. Use of peritoneal dialysis for acute kidney injury during the COVID-19 pandemic in New York City: a multicenter observational study
  31. Recurrent Nephrolithiasis Causing Kidney Failure
  32. The Urine Anion Gap: Common Misconceptions
  33. Design and Feasibility of a Randomized Controlled Pilot Trial to Reduce Exposure and Cognitive Risk Associated With Advanced Glycation End Products in Older Adults With Type 2 Diabetes
  34. Home Dialysis: A Majority Chooses It, a Minority Gets It
  35. Bilateral Renal Artery Thrombosis in a Patient With COVID-19
  36. COVID-19–Associated Acute Kidney Injury and Quantified Protein Catabolic Rate: A Likely Effect of Cytokine Storm on Muscle Protein Breakdown
  37. In Reply to ‘COVID-19–Associated Kidney Injury’
  38. State-of-the-Art Management of Hyperphosphatemia in Patients With CKD: An NKF-KDOQI Controversies Perspective
  39. Increased advanced glycation end product and meat consumption is associated with childhood wheeze: analysis of the National Health and Nutrition Examination Survey
  40. Long Term Dietary Restriction of Advanced Glycation End-Products (AGEs) in Older Adults with Type 2 Diabetes Is Feasible and Efficacious-Results from a Pilot RCT
  41. Home Dialysis Training for Fellows: Privilege or Necessity?
  42. Reverse pseudohyperkalemia is more than leukocytosis: a retrospective study
  43. COVID-19–Associated Acute Kidney Injury: A Case Series
  44. Coronavirus disease 2019 (COVID-19) hospitalized patients with acute kidney injury treated with acute peritoneal dialysis do not have infectious peritoneal dialysis effluent
  45. The association of standard Kt/V and surface area‐normalized standard Kt/V with clinical outcomes in hemodialysis patients
  46. Peritoneal Dialysis During the Coronavirus Disease-2019 (COVID-19) Pandemic: Acute Inpatient and Maintenance Outpatient Experiences
  47. Outcomes of acute pertioneal dialysis in COVID-19 patients
  48. Abstract C024: Lifestyle-associated advanced glycation end products are elevated in ER+ positive breast cancer patients, alter response to therapy, and can be targeted by lifestyle intervention
  49. Healthy eating recommendations: good for reducing dietary contribution to the body’s advanced glycation/lipoxidation end products pool?
  50. Implementation of a quality improvement strategy to increase outpatient kidney transplant referrals
  51. Acute Kidney Injury in Hospitalized Patients with COVID-19
  52. Human Brain and Serum Advanced Glycation end Products are Highly Correlated: Preliminary Results of Their Role in Alzheimer Disease and Type 2 Diabetes
  53. The potential role of dietary advanced glycation endproducts in the development of chronic non-infectious diseases: a narrative review
  54. Chronic kidney disease and kidney stones
  55. Utilization of peritoneal dialysis in the United States: Reasons for underutilization, specifically in New York State and the boroughs of New York City
  56. Adverse Effects of Autoclaved Diets on the Progression of Chronic Kidney Disease and Chronic Kidney Disease-Mineral Bone Disorder in Rats
  57. Telenephrology with Remote Peritoneal Dialysis Monitoring during Coronavirus Disease 19
  58. Inhibition of the Maillard Reaction by Phytochemicals Composing an Aqueous Coffee Silverskin Extract via a Mixed Mechanism of Action
  59. Alkali delivery in chronic hemodialysis: Would more acetate be helpful?
  60. Dietary Phosphate and the Forgotten Kidney Patient: A Critical Need for FDA Regulatory Action
  61. In vitro formation of Maillard reaction products during simulated digestion of meal-resembling systems
  62. Patient-Centric User-Interface in Automated Peritoneal Dialysis: Impact on Training and Outcomes at a Single Center
  63. Fecal microbiota analysis of polycystic kidney disease patients according to renal function: A pilot study
  64. Advanced glycation end products are elevated in estrogen receptor-positive breast cancer patients, alter response to therapy, and can be targeted by lifestyle intervention
  65. Insulin, CML , sRAGE, and markers of inflammation and oxidative stress in a normal pregnancy.
  66. Advanced glycation end products and their receptors did not show any association with body mass parameters in metabolically healthy adolescents
  67. An aspirational diet for dialysis patients: Evidence and theory
  68. Comparative evaluation of three different ELISA assays and HPLC-ESI-ITMS/MS for the analysis of N ε -carboxymethyl lysine in food samples
  69. Increased odds of metabolic syndrome with consumption of high dietary advanced glycation end products in adolescents
  70. Advanced glycation end products dietary restriction effects on bacterial gut microbiota in peritoneal dialysis patients; a randomized open label controlled trial
  71. Consumption of diets with low advanced glycation end products improves cardiometabolic parameters: meta-analysis of randomised controlled trials
  72. Reasons for admission and predictors of national 30-day readmission rates in patients with end-stage renal disease on peritoneal dialysis
  73. Molecular Mechanisms of Adverse Health Effects Associated With Excess Phosphorus Intake
  74. The link between soda intake and asthma: science points to the high-fructose corn syrup, not the preservatives: a commentary
  75. Oral AGE restriction ameliorates insulin resistance in obese individuals with the metabolic syndrome: a randomised controlled trial
  76. The AGE-RAGE Axis and Its Relationship to Markers of Cardiovascular Disease in Newly Diagnosed Diabetic Patients
  77. A Retrospective Study in Adults with Metabolic Syndrome: Diabetic Risk Factor Response to Daily Consumption of Agaricus bisporus (White Button Mushrooms)
  78. Outcomes of Dialysis Catheters Placed by Y-Tec Peritoneoscopic Technique: A Single Center Surgical Experience
  79. Dietary Advanced Glycation End Products and Their Potential Role in Cardiometabolic Disease in Children
  80. High dietary advanced glycation end products are associated with poorer spatial learning and accelerated Aβ deposition in an Alzheimer mouse model
  81. Association between probiotic and yogurt consumption and kidney disease: insights from NHANES
  82. Outcomes of dialysis catheters placed by the Y-TEC peritoneoscopic technique: a single-center surgical experience
  83. Intake of high fructose corn syrup sweetened soft drinks is associated with prevalent chronic bronchitis in U.S. Adults, ages 20–55 y
  84. Dietary Advanced Glycation End Products and Their Role in Health and Disease
  85. Elevated Serum Advanced Glycation Endproducts in Obese Indicate Risk for the Metabolic Syndrome: A Link Between Healthy and Unhealthy Obesity?
  86. Serum creatinine is not the end‐all, be‐all of renal impairment
  87. Intakes of apple juice, fruit drinks and soda are associated with prevalent asthma in US children aged 2–9 years
  88. The Low AGE Diet: A Neglected Aspect of Clinical Nephrology Practice?
  89. Effect of an advanced glycation end product-restricted diet and exercise on metabolic parameters in adult overweight men
  90. Advanced glycation end product accumulation
  91. Effect of Cholecalciferol Supplementation on Inflammation and Cellular Alloimmunity in Hemodialysis Patients: Data from a Randomized Controlled Pilot Trial
  92. Dietary advanced glycation end products are associated with decline in memory in young elderly
  93. Manifold Exchange: A Delivery Option in Managing Patients on Peritoneal Dialysis
  94. Bioavailability of vitamin D2 from enriched mushrooms in prediabetic adults: a randomized controlled trial
  95. Oral glycotoxins are a modifiable cause of dementia and the metabolic syndrome in mice and humans
  96. Dietary phosphorus intake and health
  97. What Can We Learn from the Saga of Chitosan Gums in Hyperphosphatemia Therapy?
  98. Increased circulating advanced glycation endproducts (AGEs) in acute trauma patients
  99. International Academy of Cardiology Annual Scientific Sessions 2014 19th World Congress on Heart Disease Boston, Mass., USA, July 25-28, 2014: Abstracts
  100. Phosphorus and the Kidney: What Is Known and What Is Needed
  101. Advanced Glycation End Products (AGE) and Diabetes: Cause, Effect, or Both?
  102. Introduction toDietary Phosphorus Excess and Health
  103. Potassium Balance in Dialysis Patients
  104. Dietary Phosphorus Excess: A Risk Factor in Chronic Bone, Kidney, and Cardiovascular Disease?
  105. Dietary phosphorus and kidney disease
  106. Public health impact of dietary phosphorus excess on bone and cardiovascular health in the general population
  107. Suppression of native defense mechanisms, SIRT1 and PPARγ, by dietary glycoxidants precedes disease in adult humans; relevance to lifestyle-engendered chronic diseases
  108. Combined and independent impact of diabetes mellitus and chronic kidney disease on residual platelet reactivity
  109. Contributions to Total Phosphorus Intake: All Sources Considered
  110. Role of Advanced Glycation Endproducts and Potential Therapeutic Interventions in Dialysis Patients
  111. Phosphorus-containing food additives: An insidious danger for people with chronic kidney disease
  112. Effects of Sevelamer on HbA1c, Inflammation, and Advanced Glycation End Products in Diabetic Kidney Disease
  113. PHYSIOLOGIC IMPACT OF CHRONIC KIDNEY DISEASE ON WHOLE BLOOD CLOT KINETICS AND STRENGTH
  114. The key to halting progression of CKD might be in the produce market, not in the pharmacy
  115. Serum concentration of an inflammatory glycotoxin, methylglyoxal, is associated with increased cognitive decline in elderly individuals
  116. Restriction of Advanced Glycation End Products Improves Insulin Resistance in Human Type 2 Diabetes
  117. Erratum
  118. 25‐OH‐Vitamin D Deficiency and Cellular Alloimmunity as Measured by Panel of Reactive T Cell Testing in Dialysis Patients
  119. Maternally Transmitted and Food-Derived Glycotoxins
  120. Advanced Glycation End Products in Foods and a Practical Guide to Their Reduction in the Diet
  121. Treatment of secondary hyperparathyroidism in chronic kidney disease, and its effect on the QT interval
  122. Role of oxidants/inflammation in declining renal function in chronic kidney disease and normal aging
  123. Identifying Advanced Glycation End Products as a Major Source of Oxidants in Aging: Implications for the Management and/or Prevention of Reduced Renal Function in Elderly Persons
  124. Protection against Loss of Innate Defenses in Adulthood by Low Advanced Glycation End Products (AGE) Intake: Role of the Antiinflammatory AGE Receptor-1
  125. Phosphorus Additives in Food and their Effect in Dialysis Patients
  126. Metabolic abnormalities are present in adults with elevated serum cystatin C
  127. Hereditary Nephrogenic Diabetes insipidus and Bilateral Nonobstructive Hydronephrosis
  128. Renal Hypouricemia and Absorptive Hypercalciuria: A Real Syndrome
  129. Mechanism of Normochloremic and Hyperchloremic Acidosis in Diabetic Ketoacidosis
  130. Bartter’s Syndrome Due to a Defect in Salt Reabsorption in the Distal Convoluted Tubule
  131. Pseudohypoaldosteronism following Kidney Transplantation
  132. Weight Increase Is Associated with Skeletal Muscle Immunostaining for Advanced Glycation End Products, Receptor for Advanced Glycation End Products, and Oxidation Injury
  133. Editorial: Diet, Inflammation, and Chronic Kidney Disease: Getting to the Heart of the Matter
  134. Serum 25-Hydroxyvitamin D Levels and the Prevalence of Peripheral Arterial Disease
  135. Endothelial Dysfunction in Patients with Chronic Kidney Disease Results from Advanced Glycation End Products (AGE)-Mediated Inhibition of Endothelial Nitric Oxide Synthase through RAGE Activation
  136. Advanced Glycation End Product Homeostasis
  137. Overweight, Obesity, and Elevated Serum Cystatin C Levels in Adults in the United States
  138. Dietary Advanced Glycation Endproducts and Oxidative Stress
  139. Aging and glycoxidant stress
  140. Trends in Mineral Metabolism: Kidney Early Evaluation Program (KEEP) and the National Health and Nutrition Examination Survey (NHANES) 1999-2004
  141. Opinion: How Should Dialysis Fluid Be Individualized for the Chronic Hemodialysis Patient?
  142. Advanced glycation endproducts induce podocyte apoptosis by activation of the FOXO4 transcription factor
  143. Single Oral Challenge by Advanced Glycation End Products Acutely Impairs Endothelial Function in Diabetic and Nondiabetic Subjects
  144. PHOSPHORUS METABOLISM AND MANAGEMENT IN CHRONIC KIDNEY DISEASE: Phosphorus Homeostasis in Normal Health and in Chronic Kidney Disease Patients with Special Emphasis on Dietary Phosphorus Intake
  145. Effects of low- and high-advanced glycation endproduct meals on macro- and microvascular endothelial function and oxidative stress in patients with type 2 diabetes mellitus
  146. Cerebrovascular effects of hemodialysis in chronic kidney disease
  147. Circulating Glycotoxins and Dietary Advanced Glycation Endproducts: Two Links to Inflammatory Response, Oxidative Stress, and Aging
  148. Advanced Glycation End Products and Nephrotoxicity of High-Protein Diets
  149. NORMAL HOMOCYSTEINE LEVELS IN WELL-FUNCTIONING OLDEST-OLD INDIVIDUALS DESPITE LOW KIDNEY FUNCTION
  150. Benfotiamine Prevents Macro- and Microvascular Endothelial Dysfunction and Oxidative Stress Following a Meal Rich in Advanced Glycation End Products in Individuals With Type 2 Diabetes
  151. Reduced Acute Vascular Injury and Atherosclerosis in Hyperlipidemic Mice Transgenic for Lysozyme
  152. Association of Advanced Glycoxidation End Products and Inflammation Markers with Thrombosis of Arteriovenous Grafts in Hemodialysis Patients
  153. Prevention and Reversal of Diabetic Nephropathy in db/db Mice Treated with Alagebrium (ALT-711)
  154. Oral phosphate binders in the treatment of pseudoxanthoma elasticum
  155. Insulin Resistance and Type 2 Diabetes in High-Fat–Fed Mice Are Linked to High Glycotoxin Intake
  156. Correspondence: Cinacalcet Cost and Utility in Dialysis Patients
  157. Diet-Derived Advanced Glycation End Products Are Major Contributors to the Body's AGE Pool and Induce Inflammation in Healthy Subjects
  158. Opinion: What Unique Acid-Base Considerations Exist in Dialysis Patients?
  159. K/DOQI Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease Patients: Some Therapeutic Implications
  160. Glycoxidation and Diabetic Complications: Modern Lessons and a Warning?
  161. Advanced glycoxidation end products in commonly consumed foods
  162. High Levels of Dietary Advanced Glycation End Products Transform Low-Dersity Lipoprotein Into a Potent Redox-Sensitive Mitogen-Activated Protein Kinase Stimulant in Diabetic Patients
  163. Glycoxidation and inflammation in renal failure patients
  164. The role of advanced glycation end products in the development of atherosclerosis
  165. Efficacy of reteplase in poorly functioning hemodialysis catheters
  166. Hyponatremia in peritoneal dialysis patients
  167. Effect of Exercise on the Diameter of Arteriovenous Fistulae in Hemodialysis Patients
  168. Dietary glycotoxins correlate with circulating advanced glycation end product levels in renal failure patients
  169. Treatment of ?swing point stenoses? in hemodialysis arteriovenous fistulae
  170. Hidden Sources of Phosphorus in the Typical American Diet: Does it Matter in Nephrology?
  171. Restriction of Dietary Glycotoxins Reduces Excessive Advanced Glycation End Products in Renal Failure Patients
  172. Venous access: Women are equal
  173. Vascular Screening Prior to Placement of Tunnelled and Cuffed Hemodialysis Catheters
  174. Dialysis Clinic: Unrecognized Sources of Dietary Phosphate
  175. Opinion: How Should Hyperphosphatemia Be Managed in Dialysis Patients?
  176. Obese and non-obese hemodialysis patients have a similar prevalence of functioning arteriovenous fistula using pre-operative vein mapping
  177. Relation between Interdialytic Weight Gain, Body Weight and Nutrition in Hemodialysis Patients
  178. Advanced Glycoxidation: A New Risk Factor for Cardiovascular Disease?
  179. Impact of the Surgeon on the Prevalence of Arteriovenous Fistulas
  180. ACID-BASE IN RENAL FAILURE: Acidosis in Chronic Renal Insufficiency
  181. Reteplase in the Treatment of Thrombosed Hemodialysis Grafts
  182. Gender modulates responsiveness to recombinant erythropoietin
  183. Hemodialysis access placement with preoperative noninvasive vascular mapping: Comparison between patients with and without diabetes
  184. DOQI guidelines for nutrition in long-term peritoneal dialysis patients: A dissenting view
  185. Thrombolysis of Clotted Hemodialysis Grafts with Tissue-type Plasminogen Activator
  186. Adequacy of dialysis and differences in hematocrit among dialysis facilities
  187. Relationship between phosphorus and creatinine clearance in peritoneal dialysis: Clinical implications
  188. Marked hyperlactatemia associated with severe alkalemia in a patient with thrombotic thrombocytopenic purpura
  189. The Obsession with High Dietary Protein Intake in ESRD Patients on Dialysis: Is It Justified?
  190. Carboxyhemoglobin and Lactate Levels Do Not Correlate in Critically III Patients
  191. Association of acidosis and nutritional parameters in hemodialysis patients
  192. Protein Intake Seems to Respond to Increases in Kt/V despite Baseline Kt/V Greater than 1.2
  193. Recurrence of scleroderma in a renal allograft from an identical twin sister
  194. Caloric intake in a group of peritoneal dialysis patients
  195. D-Lactic Acidosis: A Review of Clinical Presentation, Biochemical Features, and Pathophysiologic Mechanisms
  196. Middle molecule clearance does not influence protein intake in hemodialysis patients
  197. Acid production in chronic hemodialysis patients.
  198. A re-evaluation of the urinary parameters of acid production and excretion in patients with chronic renal acidosis
  199. Acid-base balance in chronic peritoneal dialysis patients
  200. Renal Stone Risk Factors in Patients With Type IV Renal Tubular Acidosis
  201. The reply
  202. Altered water metabolism in tuberculosis: Role of vasopressin
  203. Hyperkalemia in diabetes mellitus
  204. Metabolic Acidosis due to Inapparent Defects in Renal Acid Excretion in a Patient with Chronic Diarrhea
  205. Prevention of Myelinolysis in Rats by Dexamethasone or Colchicine
  206. The First Kidney Stone
  207. Case Report: Danger of Central Pontine Myelinoysis in Hypotonic Dehydration and Recommendation for Treatment
  208. Electrolyte Case Vignette: A Case of Unusual Organic Acidosis Man
  209. Acidosis-induced osteomalacia: Metabolic studies and skeletal histomorphometry
  210. Metabolic utilization and renal handling of d-lactate in men
  211. A Mechanism of Hypoxemia during Hemodialysis
  212. Salt-Losing Nephropathy